M

Mabion SA
WSE:MAB

Watchlist Manager
Mabion SA
WSE:MAB
Watchlist
Price: 8.5 PLN 4.94%
Market Cap: 137.4m PLN

Wall Street
Price Targets

MAB Price Targets Summary
Mabion SA

There are no price targets for MAB.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Mabion SA Competitors:
Price Targets
EXEL
Exelixis Inc
5% Upside
VITR
Vitrolife AB
45% Upside
2171
CARsgen Therapeutics Holdings Ltd
44% Upside
PRAX
Praxis Precision Medicines Inc
46% Upside
FYB
Formycon AG
96% Upside
VLA
Valneva SE
56% Upside
196170
Alteogen Inc
13% Upside
ADCT
ADC Therapeutics SA
121% Upside

Revenue
Forecast

Revenue Estimate
Mabion SA

For the last 13 years the compound annual growth rate for Mabion SA's revenue is 39%. The projected CAGR for the next 4 years is 3%.

39%
Past Growth
3%
Estimated Growth
Estimates Accuracy
0%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Mabion SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
28%
Average Beat

Net Income
Forecast

Net Income Estimate
Mabion SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-16%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is MAB's stock price target?
Not Available

MAB doesn't have any price targets made by Wall Street professionals.

What is Mabion SA's Revenue forecast?
Projected CAGR
3%

For the last 13 years the compound annual growth rate for Mabion SA's revenue is 39%. The projected CAGR for the next 4 years is 3%.

Back to Top